Report for: Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS)

Title	Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS)
Published in	Trials, April 2022
DOI	10.1186/s13063-022-06226-8
Pubmed ID	35422024
Authors	Seonaidh Cotton, Graham Devereux, Hassan Abbas, Andrew Briggs, Karen Campbell, Rekha Chaudhuri, Gourab Choudhury, Dana Dawson, Anthony De Soyza, Shona Fielding, Simon Gompertz, John Haughney, Chim C. Lang, Amanda J. Lee, Graeme MacLennan, William MacNee, Kirsty McCormack, Nicola McMeekin, Nicholas L. Mills, Alyn Morice, John Norrie, Mark C. Petrie, David Price, Philip Short, Jorgen Vestbo, Paul Walker, Jadwiga Wedzicha, Andrew Wilson, Brian J. Lipworth

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.

Country	Count	As %
United Kingdom	1	50%
Unknown	1	50%

Type	Count	As %
Members of the public	2	100%

Mendeley readers

The data shown below were compiled from readership statistics for 52 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Country	Count	As %
Unknown	52	100%

Readers by professional status	Count	As %
Unspecified	6	12%
Student > Master	5	10%
Researcher	3	6%
Other	2	4%
Student > Bachelor	2	4%
Other	5	10%
Unknown	29	56%

Readers by discipline	Count	As %
Unspecified	6	12%
Medicine and Dentistry	5	10%
Nursing and Health Professions	4	8%
Biochemistry, Genetics and Molecular Biology	2	4%
Economics, Econometrics and Finance	2	4%
Other	3	6%
Unknown	30	58%

Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS)